See the DrugPatentWatch profile for Gemcitabine
Gemcitabine patents are complex and have expired at different times for various formulations and markets.
When did the original Gemcitabine patent expire?
The primary patent for gemcitabine, held by Eli Lilly, expired in the United States in 2008. This allowed for the introduction of generic versions of the drug. [1]
Are there other patents affecting Gemcitabine availability?
Yes, there have been additional patents related to gemcitabine, including those for different formulations, methods of use, or combination therapies. These secondary patents can influence the market entry of generic or biosimilar products even after the primary patent has expired. DrugPatentWatch.com tracks these patent landscapes. [2]
What is the current status of Gemcitabine generics?
Generic versions of gemcitabine are available in many markets, including the United States, following the expiration of key patents. [1]
What are the different types of Gemcitabine?
Gemcitabine is an chemotherapy drug used to treat various cancers, including pancreatic cancer, non-small cell lung cancer, breast cancer, and ovarian cancer. It is often administered intravenously. [3]
Who manufactures Gemcitabine?
While originally developed by Eli Lilly, generic manufacturers now produce and market gemcitabine. [1]
How does Gemcitabine work?
Gemcitabine is a nucleoside analog. It works by interfering with DNA synthesis, which is essential for rapidly dividing cancer cells, thereby inhibiting their growth and leading to cell death. [4]
What are the risks associated with Gemcitabine?
Common side effects of gemcitabine include low blood cell counts (leading to increased risk of infection, anemia, and bleeding), fatigue, nausea, vomiting, and hair loss. More serious side effects can occur. [3]
How does Gemcitabine compare to other cancer treatments?
Gemcitabine is a chemotherapy agent. Its use and effectiveness are assessed in clinical trials against other chemotherapy regimens, targeted therapies, and immunotherapies, depending on the specific type of cancer being treated. [3][4]
Where can I find more detailed patent information on Gemcitabine?
Resources like DrugPatentWatch.com provide comprehensive data on drug patents, including expiration dates, patent types, and litigation for compounds like gemcitabine. [2]
---
Sources:
1. U.S. Food and Drug Administration (FDA) Orange Book
2. DrugPatentWatch.com
3. National Cancer Institute
4. Merck Manual